Abstract
The FDA greenlighted 17 novel cancer agents in 2018, including one with a novel endpoint in a clinical trial and one through an expanded access program. The agency also approved five biosimilars to treat cancer or the side effects of treatment.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Published OnlineFirst January 25, 2019
doi: 10.1158/2159-8290.CD-NB2019-010
New Endpoints, Programs Used for Drug Approvals
Jump to section
Advertisement